MBIO Overview

New Board Appointments: Cascade Prodrug, Inc. has appointed Dr. Manuel Litchman and Dr. Andres Gutierrez to its Board of Directors, enhancing its leadership in oncology-focused biotechnology.

Dr. Litchman's Background: Dr. Litchman brings over 30 years of experience in biopharmaceuticals, having held leadership roles at Mustang Bio and Arvinas, with a strong focus on drug development and oncology.

Dr. Gutierrez's Expertise: Dr. Gutierrez is recognized for his extensive experience in clinical development and oncology, previously serving as Chief Medical Officer at several biotech companies and leading various successful drug trials.

Company Focus: Cascade is developing hypoxia activated therapies, with their lead candidate CPD100Li showing promise against multiple tumor types and entering IND-enabling studies targeting pancreatic cancer and other hypoxic tumors.

Stock Surge: Calidi Biotherapeutics Inc (CLDI) saw a significant after-hours stock surge of 39.47%, increasing its price from $0.24 to $0.34, driven by investor confidence in its innovative cancer treatment approaches.

Market Context: The rise in CLDI's stock coincides with broader movements in the healthcare sector, including notable gains from other biotech companies, indicating heightened investor interest in potential opportunities within the industry.

Penny Stocks to Watch: Mustang Bio, Sonnet BioTherapeutics, and SaverOne 2014 Ltd. are highlighted as top penny stocks on July 8, 2025, with significant Dollar Volumes and stock price increases, particularly Mustang Bio which received FDA Orphan Drug Designation for its cancer treatment candidate.

Market Insights: The TipRanks’ Penny Stock Screener tool is utilized to identify these stocks based on various parameters, including market performance metrics like Dollar Volume, which reflects the trading activity of these companies.

Global Oncology Market Growth: The global oncology market is projected to reach hundreds of billions in revenue due to rising cancer incidence, advancements in therapies like precision medicine and immunotherapy, and increased R&D investment. Breakthrough therapy designations are accelerating drug development and approval processes, enhancing market access for pharmaceutical companies.

Oncolytics Biotech Developments: Oncolytics Biotech has reported promising clinical data for its oncolytic virus immunotherapy, pelareorep, showing significant survival benefits in metastatic pancreatic cancer and breast cancer. The company aims to advance pelareorep into registration-enabling studies, leveraging its fast-track status for regulatory efficiency.